HLA-C and cancer: In contrast to the T cell receptor (TCR), CAR enables the recognition of antigens present on cancer cells, independently of major histocompatibility complex (MHC) molecules, thus preventing cancer cells from escaping from the surveillance of the immune system due to the reduced expression of MHC on their surface [7,8,9].